CAS 218464-59-6

VPC-13566

CAS: 218464-59-6

VPC-13566

Pureza: ≥98%

Peso molecular: 258.32g/mol

Ref: 54-BUP08324

VPC-13566

CAS: 218464-59-6

VPC-13566 is a BF3-specific small molecule, which effectively inhibited the androgen receptor transcriptional activity and displaced the BAG1L peptide from the

Fórmula: C₁₈H₁₄N₂

Pureza: 99.55%

Cor e Forma: Solid

Peso molecular: 258.32

Ref: TM-T29111

VPC-13566

CAS: 218464-59-6

VPC-13566 is a novel drug that inhibits the production of an endogenous antigen. It binds to a specific molecule on the surface of prostate cancer cells and blocks the growth of these cells. VPC-13566 has been shown to be safe and effective in animal models, and it has been shown to be orally available with good pharmacokinetic properties. This drug is currently in clinical trials for prostate cancer treatment, but it may have potential for other types of cancer as well.

Fórmula: C₁₈H₁₄N₂

Pureza: Min. 95%

Peso molecular: 258.3 g/mol

Ref: 3D-TIA46459